SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 3 of 21
Word Count: 1373
Character Count: 9090

Document Content:

contemplated herein or disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock. Independent Accountants. M&K CPAS PLLC (the “Auditor”), whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

Financial Statements, etc. The financial statements, including the notes thereto and supporting schedules, included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, fairly present, in all material respects, the financial position and the
results of operations of the Company at the dates and for the periods stated therein; and such financial statements have been prepared
in conformity with U.S. generally accepted accounting principles (“GAAP”), consistently applied throughout the periods
involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be
material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules, if any, included in the Registration
Statement present fairly the information required to be stated therein. Except as included therein, no historical or pro forma financial
statements are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities
Act or the Securities Act Regulations. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the
Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission),
if any, comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to
the extent applicable. Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance
sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated
entities or other persons that may have a material current or future effect on the Company’s financial condition, changes in financial
condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any
of its direct and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus as being a subsidiary of the Company (each, a “Subsidiary” and, collectively, “Subsidiaries”),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the
ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect
to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries, or, other than
in the ordinary course of business, any grants under any stock compensation plan, and (d) there has not been any Material Adverse Change
in the Company’s long-term or short-term debt.

Authorized Capital; Options, etc. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date the
adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing
Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date, there will be no stock
options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock or any security
convertible or exercisable into shares of Common Stock, or any contracts or commitments to issue or sell shares of Common Stock or any
such options, warrants, rights or convertible securities.

Valid Issuance of Securities, etc.

Outstanding Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by
this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights
of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities
were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in
the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common
Stock were at all relevant times either registered under the Securities Act and the applicable state securities or “blue sky”
laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements.

Securities Sold Pursuant to this Agreement. The Public Shares have been duly and validly authorized for issuance and sale and,
when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject
to personal liability by reason of being such holders; and the Public Shares are not and will not be subject to the preemptive rights
of any holders of any security of the Company or similar contractual rights granted by the Company. The Representative’s Warrants
have been duly and validly authorized for issuance and sale and, when executed and delivered by the Company will be valid and binding
agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited
by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors
or by general equitable principles. When issued and delivered upon exercise of the Representative’s Warrants in accordance therewith,
the Representative Warrant Shares will be validly issued, fully paid and non-assessable; the holders thereof will not be subject to personal
liability by reason of being such holders; and the Representative Warrant Shares will not be subject to the preemptive rights of any
holders of any security of the Company or similar contractual rights granted by the Company. The Public Shares, Representative’s
Warrants and Representative Warrant Shares, when issued, will each conform in all material respects to all statements with respect thereto
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

Registration Rights of Third Parties. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities
of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include
any such securities in a registration statement to be filed by the Company.

Validity and Binding Effect of Agreement. This Agreement has been duly and validly authorized by the Company, and, when executed
and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their
respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal
and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be
subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.